Headquartered in Waltham, MA Fiscal year ends December NASDAQ: KLRA kailera.com
Kailera Therapeutics is a clinical-stage biotechnology company developing obesity treatments. It has four clinical-stage GLP-1-based product candidates covering single-, dual- and triple-agonist mechanisms in both oral and injectable forms:
- **Ribupatide injection (KAI-9531):** the lead candidate, a once-weekly injectable GLP-1/GIP receptor dual agonist. It is in the global KaiNETIC Phase 3 program (about 5,000 participants) and a U.S. high-dose Phase 2b trial.
- **Ribupatide oral (KAI-9531-T):** a once-daily oral version heading into global Phase 3 in 1H 2027.
- **Safiglipron (KAI-7535):** a once-daily oral small-molecule GLP-1 receptor agonist in a global Phase 2 trial.
- **KAI-4729:** a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist with an active U.S. IND.
The company aims to maximize weight loss, improve tolerability and address unmet needs in the obesity market. It currently generates no product revenue and funds R&D from cash and marketable securities, which management expects to last into mid-2028. Updated
Kailera cleared its End-of-Phase 2 FDA meeting for oral ribupatide, putting a global Phase 3 obesity program on the calendar for the first half of 2027. R&D spending tripled to $84.7 million as all four candidates stay on track, and management says $1.04 billion in cash funds operations into mid-2028, past the key readouts.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
Kailera Therapeutics is a clinical-stage biotechnology company developing obesity treatments.
The Wall Street consensus 12-month price target for KLRA is $42.75.
